WASHINGTON, March 25, 2025 — GO2 for Lung Cancer (GO2) announced it established the Global Advisory Council (GAC), a new group that brings together scientists, medical specialists, and other healthcare professionals from diverse disciplines who focus on GO2’s areas of impact: healthcare delivery, patient education, policy, and research. The GAC provides recommendations to guide GO2’s program and project development.  

“The GAC is an invaluable resource as GO2 for Lung Cancer continues its long-standing mission to increase survival and quality of life for those at risk, diagnosed, and living with lung cancer,” said GO2’s President and CEO Laurie Ambrose. “The diverse range of experiences, expertise, and perspectives this group offers plays a crucial role in advancing our work.” 

The GAC is the evolution of GO2’s Scientific Leadership Board into a broader, multidisciplinary group. While science remains the core foundation, the diversified expertise of GAC members better addresses emerging challenges in lung cancer care, screening access, and patient advocacy. 

“I am excited to collaborate with GO2 and colleagues who bring a depth of lung cancer expertise that spans a range of specialties,” said Memorial Cancer Institute’s Chief Scientific Officer and Medical Director, Luis E. Raez, MD, FACP, FCCP. “The GO2 Global Advisory Council is critical to ensuring that we continue to address the needs of the lung cancer community.” 

As the world’s leading organization dedicated to transforming lung cancer survivorship, GO2 is dedicated to saving, extending, and improving the lives of those vulnerable, at risk, and diagnosed with lung cancer. GAC’s members play a pivotal role in advancing GO2’s mission and achieving its key objectives: 

  • Increase the number of lung cancers diagnosed early 
  • Increase the rate of biomarker testing and use of precision medicine 
  • Increase the impact of community engagement 
  • Improve quality of life 

Current members of the GO2 Global Advisory Council include: